title: Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma.
abstract: Brentuximab vedotin induces an overall response rate of 75% in patients with relapsed/refractory Hodgkin lymphoma, but its impact on future allogeneic transplantation (allo-HCT) is not known. We retrospectively examined the records of 18 patients with relapsed/refractory Hodgkin lymphoma who were treated on brentuximab vedotin clinical trials to evaluate the efficacy and safety of subsequent reduced-intensity allo-HCT. Seventeen patients had previous autologous transplant; 6 were in complete remission, and 8 were in partial remission before allo-HCT with 12 grafts from unrelated or mismatched donors. The 1-year overall survival was 100%, progression-free survival was 92.3%, and nonrelapse mortality was 0% (median follow-up, 14 months). The incidence of acute GVHD was 27.8% and chronic GVHD was 56.3%. Brentuximab vedotin before reduced-intensity allo-HCT does not appear to adversely affect engraftment, GVHD, or survival and may provide sufficient disease control to enable reduced-intensity allo-HCT.
authors.affiliation: Department of Hematology/Hematopoietic Cell Transplantation, City of Hope, Duarte, CA 91010, USA. rchen@coh.org
authors.forename: Robert
authors.initials: R
authors.lastname: Chen
authors.forename: Joycelynne M
authors.initials: JM
authors.lastname: Palmer
authors.forename: Sandra H
authors.initials: SH
authors.lastname: Thomas
authors.forename: Ni-Chun
authors.initials: NC
authors.lastname: Tsai
authors.forename: Len
authors.initials: L
authors.lastname: Farol
authors.forename: Auayporn
authors.initials: A
authors.lastname: Nademanee
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Forman
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Gopal
mesh_terms: D000328:Adult; D000079963:Brentuximab Vedotin; D002452:Cell Count; D019008:Drug Resistance, Neoplasm / Q000502:physiology; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000166:cytology; D006689:Hodgkin Disease / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000627:therapeutic use*; D008875:Middle Aged; D012008:Recurrence; D012189:Retrospective Studies; D016019:Survival Analysis; D019172:Transplantation Conditioning; D014184:Transplantation, Homologous; D017211:Treatment Failure; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D000079963:Brentuximab Vedotin